INTRODUCTION
Diabetes mellitus (DM) is a group of metabolic disorders characterized by the loss of functional pancreatic b cell mass, leading to insufficient insulin secretion (Talchai et al., 2012; Weir and Bonner-Weir, 2013) . Current diabetes therapies cannot prevent b cell death or promote regeneration of remaining b cells and rarely result in complete long-term metabolic normalization. Thus, one of the main strategies in improving current DM therapy is to define and validate novel approaches to protect and restore b cell mass (Donath and Halban, 2004) . In both rodents and humans, b cells are formed by neogenesis from endocrine progenitor cells that proliferate extensively during the end of embryogenesis and early postnatal period to reach the proper adult b cell mass (Dhawan et al., 2007; Meier et al., 2008) .
A number of cellular insults can disrupt protein folding and cause accumulation of unfolded proteins, triggering endoplasmic reticulum (ER) stress, and, if prolonged, lead to ERstress-induced apoptosis (Szegezdi et al., 2006) . Accumulation and aggregation of unfolded proteins result in dissociation of general ER stress chaperone GRP78/Bip from ER stress sensors PERK, ATF6, and IRE1 and activation of downstream signaling unfolded protein response (UPR) cascades, finally resulting in decreased protein synthesis, increased protein folding capacity, and degradation of misfolded proteins (Szegezdi et al., 2006; Walter and Ron, 2011) . Importantly, alterations in proteins involved in ER stress and UPR are linked to diabetes in humans and mice, suggesting that unresolved ER stress is involved in the pathogenesis of b cell loss in type 1 and type 2 diabetes (Delé pine et al., 2000; Eizirik et al., 2008 Eizirik et al., , 2013 Hetz, 2012) .
MANF together with cerebral dopamine neurotrophic factor forms a new, highly evolutionarily conserved protein family, efficiently protecting and repairing midbrain dopaminergic neurons in animal models of Parkinson's disease and protecting cardiac myocytes in myocardial infarction and cortical neurons against ischemic stroke (Airavaara et al., 2009; Glembotski et al., 2012; Hellman et al., 2011; Lindholm et al., 2007 Lindholm et al., , 2008 Lindholm and Saarma, 2010; Petrova et al., 2003; Voutilainen et al., 2009) . However, the cytoprotective mechanisms of MANF are not known.
MANF mRNA and protein are widely expressed in most human and mouse organs with high levels in glandular cells of secretory tissues such as pancreas and salivary gland (Lindholm et al., 2008) . Intracellularly, MANF localizes to the luminal ER, where it interacts with the chaperone GRP78 and is secreted in response to experimental ER stress in vitro (Apostolou et al., 2008; Glembotski et al., 2012; Lindholm and Saarma, 2010; Mizobuchi et al., 2007) . Thus, recent studies suggest that MANF is an ER-stress-inducible protein for several cell populations.
To understand the physiological role of MANF in vivo, we generated MANF knockout mice (Manf regions of pancreas that had been transduced to overexpress MANF. Our results demonstrate that MANF specifically promotes b cell proliferation and survival, thereby constituting a promising therapeutic agent for b cell protection and regeneration.
RESULTS

Loss of MANF in Mice Results in Growth Retardation and Diabetes
To understand the physiological role of MANF in vivo, we generated MANF knockout mice (Manf À/À ) from an embryonic stem cell clone MANF_D06 (EPD0162_3_D06; C57Bl/6N-Manf tm1a(KOMP)Wtsi ), containing a b-galactosidase reporter cassette with a strong splice acceptor site inserted in the intron between exon 2 and exon 3 of the Manf gene, creating a constitutive null mutation through splicing of exon 2 to the reporter cassette (Figure 1A) . We confirmed that MANF full-length mRNA and protein were not expressed in tissues of Manf À/À mice (Figures S1A and S1B). We found that MANF-deficient mice display progressive gender-independent growth retardation ( Figure 1B ). In addition, the body size and fat pad weights were significantly reduced in Manf À/À male mice compared to wild-type (WT) mice (Figures S1D-S1F). At 8-12 weeks of age, the health of the mutant mice quickly deteriorated and the animals were euthanized.
The blood glucose levels of ad libitum fed animals were within normal range for Manf À/À mice compared to wild-type Manf +/+ measured at postnatal day 1 (P1) and at P14 ( Figure 1C ). However, at P56, the Manf À/À mice were severely hyperglycemic ( Figure 1C ) and they consumed significantly more water than Manf +/+ littermates ( Figure S1G ). Glucose tolerance test showed a severely compromised glucose clearance compared to Manf +/+ mice already at P14 ( Figure 1D ). In addition, significantly reduced levels of insulin were observed from sera of fed P28 Manf À/À mice compared to Manf +/+ littermates, and at P56, insulin was barely detectable ( Figure 1E ). Insulin tolerance test suggested intact insulin sensitivity in the Manf À/À mice ( Figure 1F ).
Circulating glucose-stimulated insulin levels were dramatically decreased in P56 Manf À/À mice ( Figure 1G ). Although remaining islets derived from diabetic P35 Manf À/À mice secreted less insulin than WT islets after an overnight culture period ( Figure 1H ), their capacity to secrete insulin relative to cellular insulin content did not differ in response to glucose or glucose plus IBMX ( Figure 1I ). The diabetic phenotype was confirmed in independent conditional PGK 2F ). Quantification of b cell mass revealed no difference between genotypes at embryonic day 18.5 (E18.5), whereas already by P1, the reduction in Manf À/À pancreases was 50%
and by P56, 85% ( Figure 2G ). Proliferation is important for the b cell expansion during late embryogenesis and in the neonatal period to reach the proper b cell mass (Dhawan et al., 2007) . There were no differences between genotypes in the number of proliferating (bromodeoxyuridine+ or Ki67+) insulin-positive b cells quantified from pancreases at E18.5 ( Figures 2H, S3A , and S3B), but a significant reduction in Ki67+ b cells was observed in P1 and P14 Manf À/À mice ( Figure 2H ). Importantly, the number of proliferating exocrine acinar cells did not differ between genotypes ( Figure 2I ). Quantification of TUNEL+ b cells revealed increased b cell apoptosis in Manf À/À pancreas at P14
and P56 that coincided with the reduction of b cell mass (Figures 2J and S3C) . Glucagon immunohistochemistry showed a normal a cell mass, indicating that the phenotype is b cell specific ( Figures S3D-S3J ).
Despite Its Universal Expression Pattern, MANF Deficiency Affects b Cells
Expression of MANF has previously been detected in several tissues, including pancreatic acinar cells at E17 and in adult pancreatic islet cells (Lindholm et al., 2008; Mizobuchi et al., 2007) . We studied in more detail the expression of MANF in mouse pancreas by double immunohistochemistry with insulin and MANF antibodies. High MANF expression was colocalized with insulin-positive b cells in mouse islets ( Figure S4B , arrowhead). However, MANF-positive immunostaining was also detected in exocrine acinar cells ( Figure S4B , arrow). Importantly, none to very weak background staining of MANF was detected in Manf À/À pancreas ( Figure S4E ). Similarly to expression in mouse, we detected MANF expression in the islets and exocrine tissue of human adult pancreas tissue ( Figures  S4G-S4I ). Consistent with progressively reduced b cell mass from P1 Manf À/À pancreas, there was significantly reduced expression of glucose transporter 2 (Glut2), insulin1/insulin2 (Ins1/2), and Pdx1 and a trend toward reduced glucokinase (Gck) expression in islets of P1 Manf À/À mice ( Figures 3B-3D ). Importantly, reduced expression of these b cell markers was not observed in pancreases of E18.5 mice ( Figure 3A ). Along with other b cell-specific genes, also MafA mRNA expression was significantly reduced already in P1 Manf À/À islets ( Figures 3B-3D ).
GLUT2 immunohistochemistry showed clearly reduced membrane localization and expression of GLUT2 protein in P14 and P56 Manf À/À b cells ( Figures 3E-3J ). Taken together, our data indicate that the timing of the progressive loss of b cell phenotype occurs postnatally in Manf À/À islets. Figure 4A ). There was a trend toward higher levels of Atf4, Grp78, Chop, spliced Xbp1, and Atf6a mRNA expression in islets from P1 Manf À/À mice compared to WT ( Figure 4B ). A significant elevation of mRNA levels for Atf4, Grp78, Chop, and Atf6a was found in the islets isolated from P14 Manf À/À pancreases compared to WT islets ( Figure 4C ). Taken together, our results demonstrate that loss of b cell phenotype is preceded by upregulation of genes in IRE1 pathway starting at E18.5 followed by activation of PERK and ATF6 pathways ( Figure 4F ). Furthermore, quantification of phosphorylated (p)eIF2a band intensities in relation to total levels of (t)eIF2a by western blot analysis revealed a higher level of phosphorylated eIF2a in P14, P28, and P56 Manf À/À islets ( Figures 4D and 4E ), demonstrating that the PERK pathway was constitutively activated in the postnatal Manf À/À islets ( Figure 4F ).
Loss of MANF Results in Activated Endoplasmic
Recombinant MANF Induces Proliferation of Pancreatic b Cells In Vitro and In Vivo
We assessed whether recombinant human MANF protein could directly affect mouse b cell proliferation in vitro. Compared to islets cultured without added growth factors, MANF significantly increased b cell proliferation ( Figure 5A ). Importantly, MANF together with placental lactogen (PL), a potent mitogen for b cells, further increased the number of proliferating b cells. Hence, extracellular MANF has a direct proliferative effect on mouse b cells, implying the presence of a yet unidentified receptor for MANF on the b cells capable of mediating intracellular mitogenic signaling cascades. Our observed effects of MANF removal from b cells in vivo and exogenous recombinant MANF protein on b cells in vitro suggested that MANF might be therapeutic in a rodent model of diabetes. We therefore tested whether overexpression of MANF by intrapancreatic delivery of a MANF-expressing adenoassociated virus serotype 6 (AAV6) in mice affects b cell proliferation and survival after streptozotocin-induced b cell depletion. Three weeks after AAV6-MANF or AAV6-RFP (a control red fluorescent protein) administration, animals were injected with low-dose streptozotocin (STZ) for 5 consecutive days to induce b cell deficiency ( Figure 5B ). Robust, patchy expression of MANF or RFP ( Figures S5B, S5F , and S5J) was observed in islet b cells (transduction efficiency 4.3% ± 1.5%) and exocrine tissue (4.2% ± 1.5% cells transduced), confirming a successful delivery and overexpression of MANF and RFP. Consistent with elevated blood glucose levels and reduced serum insulin levels, STZ-induced b cell loss was detected in the islets from mice treated with STZ ( Figures S5H and S5L-S5N ).
Insulin immunoreactive islets were larger in the STZ-injected, AAV6-MANF-treated pancreatic sections compared to the AAV6-RFP-treated mice ( Figures 5C, S5H, and S5L) . Although the blood glucose and insulin levels were comparable between AAV6-MANF and AAV6-RFP STZ-injected groups, we found a significantly higher b cell proliferation rate in the STZ-injected, AAV6-MANF-treated groups compared to both the buffer-injected (nonlesioned) AAV6-RFP and the STZ-injected Quantitative RT-PCR for mRNA levels of b cell-specific genes Glut2, Ins1/2, Pdx-1, MafA, and Gck in E18.5 pancreases (A) and islets from P1 (B), P14 (C), and P56 (D) pancreases, n = 4-10 per group. Mean ± SEM, *p < 0.05, **p < 0.01, versus the corresponding control. GLUT2 immunohistochemistry of pancreas sections from WT and Manf À/À mice at P1 (E and H), P14 (F and I), and P56 (G and J); scale bar, 100 mm.
See also Figure S4 . Figures 5D, S5M , and S5N), demonstrating that overexpression of MANF could enhance b cell proliferation and regeneration in vivo. Importantly, we found no significant difference in the number of proliferating exocrine acinar cells between treatment groups, suggesting that the proliferative effect of MANF was specific for endocrine pancreas ( Figure 5E ). Additionally, AAV6-MANF significantly protected against b cell death compared to the AAV6-RFP STZ-injected group ( Figure 5F ). Taken together, our results demonstrate that gene therapy using MANF is able to induce b cell proliferation and regeneration and protect b cells from apoptosis in an experimental diabetes model.
AAV6-RFP groups (
DISCUSSION
In order to understand the physiological role of MANF in mammals, we generated MANF-deficient mice. Surprisingly, MANF deficiency in mice leads to a progressive loss of b cells, resulting in diabetes mellitus due to reduced b cell proliferation and enhanced b cell death. The severe diabetic phenotype of global Manf À/À mice was unexpected because inactivation of MANF in fruit fly and knockdown of Manf mRNA expression in zebrafish causes a dopaminergic phenotype (Chen et al., 2012; Palgi et al., 2009) 
. Conditional removal of MANF specifically from the pancreas in Pdx1
Cre/+ :: Manf fl/fl mice leads to a diabetic phenotype similar to the global knockout mice. However, inactivation of MANF by Nestin-Cre expression did not result in a diabetic phenotype. In Nestin-Cre mice, Cre recombinase activity is detected in the CNS by E11, in mesenchymal and epithelial cells of the early pancreatic primordium, and in scattered acinar cells of the exocrine pancreas in adults, but not in islet endocrine cells (Delacour et al., 2004) . Thus, our results obtained from conditional removal of MANF strongly suggest that MANF produced locally in the islets is important for the b cell proliferation and survival.
Previous studies have shown that MANF is upregulated in ER stress in vitro and can protect several cell populations from ERstress-induced cell death in vivo (Airavaara et al., 2009; Apostolou et al., 2008; Glembotski et al., 2012; Voutilainen et al., 2009 ). Interestingly, MANF protein level was also increased in the b cells of diabetic Akita mice in which ER stress is caused by the accumulation of proinsulin in the ER (Mizobuchi et al., 2007) . Furthermore, MANF total knockdown in fruit fly embryos has revealed increased expression of several genes involved in ER stress and increased eIF2a phosphorylation (Palgi et al., 2012) .
Here, we show that lack of MANF in vivo leads to ER stress and chronic UPR activation in pancreatic islets. The activation of UPR is clearly evident already at E18.5 by increased expression of spliced Xbp1 and Chop mRNA, followed by the upregulation of the general ER stress marker Grp78 and genes in the PERK and ATF6 pathways. Importantly, we found no difference in b cell mass or in the number of proliferating b cells quantified from WT and Manf À/À pancreases at E18.5. Similarly, b cell-specific genes Glut2, Ins1/2, Pdx1, and Gck were not significantly downregulated in Manf À/À pancreas at E18.5, indicating that ER stress precedes the impaired b cell function. As MANF is widely expressed in several tissues, the question arises why global MANF knockdown results in such a robust b cell phenotype. Increased phosphorylation of eIF2a that is known to lead to a global decrease in mRNA translation initiation is tolerated poorly by b cells (Cnop et al., 2007) . In addition, prolonged ATF6 activation downregulates transcription factors PDX1 and MAFA, both critical for promoting expression of insulin and important for b cell function (Artner et al., 2010; Seo et al., 2008) . Thus, the current evidence suggests that UPR activation detected already at E18.5 in Manf À/À islets affects the expression of b cell-specific proteins, leading to decreased insulin expression, reduced b cell proliferation, and increased b cell death. Several factors contributing to the regulation of b cell mass, including insulin-like growth factors (IGF-I and IGF-II), glucagon-like peptide-1, prolactin, growth hormone, and placental lactogens, are potential therapeutic targets for expansion of the human b cell mass (Tarabra et al., 2012) . However, therapeutic use of some of these hormones and growth factors has been limited by the lack of specificity, stimulation of uncontrolled b cell growth, and adverse effects on b cell function. Furthermore, knockdown studies have revealed that many of these factors are not essential for physiological b cell expansion and survival (Tarabra et al., 2012; Vasavada et al., 2006) . Recently, a potential specific growth factor for b cells, named betatrophin (alias ANGPTL8), was identified (Yi et al., 2013) . However, the finding that deletion of ANGPTL8 did not affect b cell mass or glucose metabolism (Wang et al., 2013) indicates that its physiological action on b cells is very different from MANF.
Here, we show that recombinant MANF is a potent stimulator of b cell proliferation in vitro, constituting a protein with therapeutic potential for stimulating b cell renewal. Additionally, our work provides tools for finding the mechanism of MANF action by identifying its receptor(s) and signaling pathways in b cells.
Our in vivo gene therapy experiment using AAV-6 MANF showed that, despite low transduction efficiency (only $4% of the b cells) of pancreatic cells, MANF promotes normal islet morphology and specifically enhances b cell proliferation and protects b cells in mice in an experimental diabetes model. Future experiments using higher virus titers, longer MANF overexpression, and different diabetic models are clearly needed to validate the therapeutic potential of MANF.
The severe postnatal decline in b cell mass in the Manf À/À mice and our in vitro and in vivo data indicate that MANF may be one of the most potent secreted growth factors for regulating both b cell proliferation and for maintaining b cell mass in mice. Finally, high MANF expression in human pancreas suggests that MANF might have similar b cell mitogenic effects also in humans. Future studies will evaluate the potential of MANF to protect and regenerate functional b cells as a therapeutic agent for treating diabetes.
EXPERIMENTAL PROCEDURES
Manf-Targeted ESC Clone
The targeted mouse embryonic stem cell (ESC) clone MANF_D06 (EPD0162_3_D06, C57Bl/6N-Manf tm1a(KOMP)Wtsi ) was generated by the trans-National Institutes of Health (NIH) Knockout Mouse Project (KOMP) and obtained from the KOMP Repository (http://www.komp.org). Genetically modified ESCs were aggregated with morula-stage preimplantation embryos (ICR strain) at the GM mouse unit of University of Helsinki. (E) Quantified intensities of western blot bands of phosphorylated (p)EIF2a was compared to total amount of (t)EIF2a and tEIF2a to intensities of GAPDH, n = islets from two to three pancreases per genotype. ) animals in hybrid C57Bl6 3 ICR mixed background. The day of vaginal plug was designated as E0.5. Age-matched NMRI male mice for the in vivo MLD-STZ experiment were obtained from Harlan Teklan, UK. Pancreatic islets were isolated from age-matched 8-week-old C57Bl/6JRccHsd (Harlan) female mice in b cell proliferation assay.
Genomic DNA Isolation and Genotyping DNA was isolated from earmarks, and genotyping was carried out by PCR using primers described in Supplemental Experimental Procedures.
Islet Isolation and In Vitro Insulin Release
Pancreases from mice were treated with collagenase P digestion (Collagenase P; Roche Diagnostics) followed by hand-picking of islets under a stereomicroscope (Miettinen et al., 2006) . Human pancreatic tissue was obtained at autopsy at the Helsinki University Central Hospital, and isolated human islets were received from Uppsala, Sweden through the European Consortium for Islet Transplantation. In vitro insulin release assay was performed as previously described (Miettinen et al., 2006) . (E) Acinar cell proliferation in AAV6-virus-injected, nondiabetic, and STZ-treated mice, n = 6 per group. NS, not significant. (F) Islet cell death assessed by TUNEL followed by insulin staining, n = 5 to 6 per group. Mean ± SEM, **p < 0.01, ***p < 0.001 versus corresponding control. See also Figure S5 .
activating downstream signaling UPR cascades. Phosphorylated PERK blocks global mRNA translation by phosphorylating eIF2a subunit. Transcription factor ATF4 escapes eIF2a translational control and in turn induces transcription of proapoptotic gene, Chop. Active ATF6 translocates to the nucleus, where it induces chaperone genes such as Grp78 and Xbp1 and controls genes involved in the ER-associated degradation. Activated IRE1a removes by splicing an intron from Xbp1, generating spliced Xbp1 (Xbp1s), which when translated to a transcription factor activates genes for ER-associated decay and chaperons for protein folding. Food and Water Intake and Energy Expenditure Feeding and drinking, energy expenditure (O 2 consumption and CO 2 production using indirect calorimetry), respiratory exchange ratio, and locomotor activity were measured using CLAMS monitoring system (Columbus Instruments) in 6-week-old mice. For detailed description, see Supplemental Experimental Procedures.
Western Analysis
Western blot was performed according to standard protocols and as described in the Supplemental Experimental Procedures.
Immunohistochemistry and Quantification of b and a Cell Mass and Islet Size
Immunohistochemistry was performed according to standard procedures, and b and a cell mass analysis and islet size measurements were performed as described in the Supplemental Experimental Procedures.
Analysis of Blood Samples
Blood samples from mice were collected from the tail vein or terminal blood from heart and assayed for glucose (Accucheck Aviva Glucometer; Roche Diagnostics) and insulin (ultrasensitive mouse insulin ELISA; Crystal Chem). For glucose challenge test, P14 mice were fasted for 1 hr and P56 mice 5 to 6 hr before animals were injected intraperitoneally (i.p.) with 2 g/kg body weight of glucose (in 0.9% NaCl). Insulin tolerance test was performed on 2 hr-fasted P42 male mice by injection of 1U/kg i.p. insulin (diluted in 0.9% saline; Humulin Regular; Eli Lilly) and monitoring of blood glucose levels from tail vein every 15 min for 60 min.
AAV Vector Construction and In Vivo Administration of AAV Vectors
The construction of the AAV packaging plasmids, generation of AAV vectors, and retrograde pancreatic duct injections were carried out as described in Supplemental Experimental Procedures. Three weeks after AAV administration, AAV6-MANF and AAV6-RFP animals were injected on 5 consecutive days with a low dose of streptozotocin (40 mg/kg/day, i.p., freshly dissolved in 0.1 M citrate buffer [pH 4.5]).
In Vitro b Cell Proliferation Assay Islets from female, virgin, 8-week-old mice were isolated as described above. Equal numbers of islets per well were treated for 5 days with recombinant human placental lactogen (500 ng/ml; Affiland) or recombinant human MANF (100 ng/ml; Icosagen) or a mixture of both. The relative numbers of proliferating b cells were quantified from wells of five repeats per treatment (details in Supplemental Experimental Procedures).
Statistical Analysis
Unless otherwise stated, significance of differences between groups was analyzed by Student's unpaired two-tailed t test using Microsoft Excel software. Differences between more than two groups were calculated by one-way ANOVA followed by appropriate post hoc test using SPSS PASW Statistics 18 program. For statistical analysis of islet size distribution, we used GraphPad Prism 5, data were subjected to Kruskal-Wallis one-way ANOVA test, and differences were evaluated by Dunn's Multiple Comparison Test. Results are expressed as mean ± SEM. Results were considered significant at p < 0.05.
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